Rafarma Pharmaceuticals, a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, just announced that ZAO “Rafarma” has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.
The antibiotic is typically used in combination for the treatment of pneumonia, bacterial meningitis, gonorrhea, and in pediatrics for the prevention of sepsis. According to today’s press release, market capacity of CEFTRIAXONE in the Russian Federation last year totaled USD $85.7 million dollars, an increase of 20% compared to its capacity in 2011.
Dave Anderson, CEO of Rafarma Pharmaceuticals, said, “Registering this product is complementary to our goal of producing high-quality pharmaceutical products. Rafarma is positioned to meet rising market demand for CEFTRIAXONE utilizing our state-of-the-art research facility and staff as we continue efforts to expand our product portfolio.”
“I’d also like to clarify that Rafarma’s earlier announcement reporting its status as 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation in no way limits our ability to produce and manufacture products for qualified buyers globally,” added Mr. Anderson. “We will offer CEFTRIAXONE, as well as all other products we produce, to the international market.”
For more information, visit www.Rafarma.com
Let us hear your thoughts: Rafarma Pharmaceuticals, Inc. Message Board